1. Introduction {#sec1}
===============

Psoriasis is a common chronic relapsing inflammatory skin disorder that is induced and sustained by lymphocytes infiltrating the skin, affecting about 2-3% of the population \[[@B1], [@B2]\]. Although its etiology is not clear, we know that it is not only a skin-restricted disease but also a systemic inflammatory immune disorder which is influenced by various genetic and environmental factors \[[@B3]\]. As with many autoimmune diseases, abnormal apoptosis has important implications in psoriasis biology \[[@B4], [@B5]\]. The data show that, in addition to the hyperproliferation of keratinocytes, deceleration in keratinocyte apoptosis is also a significant pathological change observed in psoriasis \[[@B6]--[@B8]\]. Keratinocytes from the lesion of psoriasis are resistant to induction of apoptosis compared to keratinocytes from normal skin \[[@B9]\]. However, the current data on the apoptosis of psoriatic keratinocytes is limited. Therefore, there is a need to better understand the mechanisms of apoptosis in the progression of psoriasis and to identify potential biomarkers for prognostic prediction.

Apoptosis, a unique physiological process genetically controlling programmed cell death, is essential for maintaining normal tissue homeostasis, cell differentiation, and development \[[@B4]\]. In the skin, the death of apoptotic cells regulates keratinocyte proliferation and the formation of the stratum corneum \[[@B10]\]. Caspases (CASPs) are cysteine-dependent aspartate-specific proteases that play a central role in the induction, transduction, and amplification of apoptotic signals in cells and thus determination of cell fate \[[@B11], [@B12]\]. CASPs can be generally classified into three groups based on their biological functions: inflammatory CASPs (CASP1, CASP4, CASP15, CASP11, and CASP12, apoptosis initiator (CASP2, CASP8, CASP9, and CASP10), and apoptosis executioner (CASP3, CASP6, and CASP7). CASP14 plays an important role in the terminal differentiation of epidermal keratinocytes \[[@B13]\]. The apoptotic pathways involved in keratinocyte apoptosis include several mechanisms. But all have to go through the caspase family. CASPs are sequentially activated in apoptosis, and any CASP may lead to apoptosis aberration. The increase of epidermal thickness in psoriasis may be related to the abnormality of the apoptotic pathway \[[@B2]\]. Some of them have even been reported to have abnormal expression in the lesions of psoriasis \[[@B1], [@B14], [@B15]\].

Psoriasis is a widespread autoimmune disease and systemic inflammatory disorder with which many of comorbidities (e.g., diabetes, cardiovascular diseases, Crohn\'s disease, lymphoma, and cancer) are associated. Patients with psoriasis tend to have an increased risk of cancer \[[@B16]\]. Single nucleotide polymorphisms (SNPs) influence the expression or the activities of caspase enzymes. Several*CASP* genes polymorphisms have been found to be associated with kinds of cancers \[[@B17]--[@B21]\] and autoimmune inflammatory diseases, such as rheumatoid arthritis \[[@B5]\], coronary artery disease \[[@B23]\], Kawasaki disease \[[@B24]\], acute pancreatitis \[[@B25]\], and ischemic stroke \[[@B26]\], but the relationship with psoriasis has not been studied. And gene expression profiles showed significant differences in the expression of CASP7 and CASP8 between psoriatic lesions and psoriatic nonlesions. With this in mind, we designed a case-control trial to explore the relationship between*CASP* genes and psoriasis vulgaris (PsV) using polymorphism association studies in order to elucidate the pathogenic mechanisms of PsV.

2. Materials and Methods {#sec2}
========================

2.1. Study Population {#sec2.1}
---------------------

The present case-control study included 540 patients with PsV randomly enrolled from the Second Affiliated Hospital of Harbin Medical University from January 2013 to April 2017 and 612 healthy controls randomly recruited from the same hospital during routine health examinations performed during the same period. All samples we collected were between the ages of 5 and 85. The patients with PsV were diagnosed by at least two clinical dermatologists in the Department of Dermatology. All subjects were of Han Chinese descent in northeastern China; all patients underwent a standardized clinical evaluation and the healthy controls were without any known history of PsV (including three levels of relatives).

The basic information of all subjects including sex, age, and demographic characteristics (in the case group), including age of onset, severity grade, and family history (including three levels of relatives), was obtained from self-reported questionnaires and medical records. Subjects with systemic, infectious, autoimmune, atopic, or malignant disease were excluded.

All of the participants provided written informed consent before participating in the study. All the procedures followed were in accordance with the ethical standards of the 2nd Affiliated Hospital of Harbin Medical University on human experimentation. The Ethics Committees of the 2nd Affiliated Hospital of Harbin Medical University approved this study. All procedures were in accordance with the 1975 Declaration of Helsinki and its later amendments.

2.2. DNA Extraction {#sec2.2}
-------------------

Genomic DNA was prepared from 2 mL of intravenous whole blood using the QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer\'s instructions. DNA samples were stored in a freezer (Mitsubishi, Japan) at −20°C.

2.3. Selection of Polymorphisms {#sec2.3}
-------------------------------

Seventeen polymorphisms in 11*CASP* genes were examined. We did not find any SNPs in*CASP2* with the appropriate allele frequency in Han population of northeastern China.*CASP11*,*CASP13*, and*CASP15*do not exist in humans. For the 17 common SNPs, 10 polymorphisms (*CASP3* rs2705897 and rs4647610,*CASP5* rs507879,*CASP7* rs2227310,*CASP8* rs6704688 and rs2293554,*CASP9* rs4233532 and rs1052576, and*CASP10* rs12613347 and rs13006529) were selected based on the literature suggesting that these SNPs were associated with the risk of various cancers and autoimmune diseases. For*CASP1*,*CASP4*,*CASP6*,*CASP7*,*CASP12*, and*CASP14*, we utilized the International HapMap Project database (<http://hapmap.ncbi.nlm.nih.gov/>) and the NCBI dbSNP database (<https://www.ncbi.nlm.nih.gov/projects/SNP/>) to select potentially functional SNPs. We set the cutoff at a minor allele frequency of more than 0.05 for the Han Chinese in Beijing (HCB) population and linkage disequilibrium (LD) patterns with r^2^ values of more than 0.8. Based on the different distributions of SNPs, seven representative common SNPs (*CASP1* rs2282659,*CASP4* rs547584 and rs672016,*CASP6* rs5030545,*CASP7* rs17090911,*CASP12* rs506601, and*CASP14* rs3181304) were finally selected for genotyping.

2.4. Genotyping {#sec2.4}
---------------

Genotyping was performed by the Improved Multiple Ligase Detection Reaction technique developed by Genesky Biotechnologies Inc. (Shanghai, China) \[[@B27]\]. Target DNA sequences were amplified using a multiplex polymerase chain reaction (PCR) method with specific primers and probes. The details are shown in Supplementary Tables [S1](#supplementary-material-1){ref-type="supplementary-material"} and [S2](#supplementary-material-1){ref-type="supplementary-material"}.

Data analysis was carried out using GeneMapper Software version 4.1. For quality control, genotyping was carried out without knowledge of group status. We randomly selected about 10% of samples for further verification and obtained a concordance rate of 100%.

2.5. Statistics {#sec2.5}
---------------

The demographic characteristics were calculated by SPSS version 19.0 (IBM, Chicago, IL, USA). *χ*^2^ tests and Student\'s t-tests were used to compare clinical characteristics between the two groups. The Hardy-Weinberg equilibrium (HWE; evaluated at \< 0.001) test was determined using *χ*^2^ tests. Associations between candidate SNPs and PsV risk were determined based on the distributions of allele and genotypic frequencies along with the additive, dominant, recessive, and heterozygous models. Multiple logistic regressions analyses were used to analyze the genotype frequency between groups. The gene interaction analysis (gene epistasis analysis) was performed using the Epistasis Module of Plink. Odds ratios and 95% confidence intervals were calculated to determine the relative risk of PsV, and 10,000 permutations were performed for the multiple test correction. The LD and haplotype were computed and constructed from the genotypes of these polymorphic markers by Haploview 4.0, and LD r^2^ values were limited to 0.8. All comparisons were two sided, and results with *P* values of less than 0.05 were considered statistically significant.

3. Results {#sec3}
==========

3.1. Participants {#sec3.1}
-----------------

Basic information and the clinical characteristics of the participants are shown in [Table 1](#tab1){ref-type="table"}. No significant differences were observed in these factors between the two groups.

3.2. Single SNP Analysis {#sec3.2}
------------------------

The genotype and allele frequencies of the SNPs in the PsV group and control group are shown in Tables [2](#tab2){ref-type="table"} and [3](#tab3){ref-type="table"}. All genotype distributions of cases and controls passed the H-W test. For the*CASP8* rs6704688 polymorphism, the major C allele (risk allele) was present in 76.9% of patients and 75.3% of controls. The additive model (C versus T) distribution and the heterozygous model (TT + CC versus TC) distribution were significantly different between cases and controls (*P* = 0.0169,*P\'* = 0.0179;*P* = 0.0126, and*P\'* = 0.0149, respectively). No associations between the other 16 SNPs and the risk of PsV were observed in this study. However, there were correlations among*CASP8* rs6704688 in the dominant model (CC versus CT + TT;*P* = 0.0679,*P\'* = 0.0974),*CASP9* rs4233532 in the heterozygous model (CC + TT versus CT;*P* = 0.0773,*P\'* = 0.0821),*CASP10* rs12613347 in the recessive model (CC + CT versus TT;*P* = 0.8247,*P\'* = 0.8681) and heterozygous model (TT + CC versus TC;*P* = 0.8829,*P\'* = 0.9316), and*CASP10* rs13006529 in the additive model (T versus A;*P* = 0.0846,*P\'* = 0.0806). These results were marginally significant with regard to PsV risk and may become significant if an increased sample size is evaluated.

3.3. Interaction Analysis {#sec3.3}
-------------------------

We performed a gene-gene interaction analysis on all samples. We found that the interaction of*CASP10* -*CASP1, CASP10*-*CASP3, CASP10*-*CASP4, CASP10*-*CASP9, CASP10*-*CASP12, CASP8 - CASP3, CASP8 - CASP4*, and*CASP1 - CASP12* is important for the risk of psoriasis ([Table 4](#tab4){ref-type="table"}). Additional results that were not found to be significant were shown in Supplementary Materials ([Table S3](#supplementary-material-1){ref-type="supplementary-material"}). The age group under 40 is a high-risk age group for psoriasis. The analysis of intergene interactions in this age group found that the interaction between 10 pairs of genes was significant for the risk of psoriasis. They are the interaction of*CASP8* -*CASP10*,*CASP3* -*CASP4*,*CASP3 - CASP6, CASP3*-*CASP8*,*CASP1* -*CASP8, CASP1*-*CASP10*,*CASP6* -*CASP7*, and*CASP7*-*CASP9* ([Table 5](#tab5){ref-type="table"}). Additional results that were not found to be significant were shown in Supplementary Materials ([Table S4](#supplementary-material-1){ref-type="supplementary-material"}).

3.4. Haplotype Analysis {#sec3.4}
-----------------------

The haplotype blocks were imputed by Haploview for each of the 11 genes and we obtained four haplotypes in*CASP3* and*CASP4* and three haplotypes in*CASP7*,*CASP8*,*CASP9*, and*CASP10*. The results are shown in [Table 6](#tab6){ref-type="table"}. The results showed that, among the 21 haplotypes, the*CASP3* haplotype TT and*CASP4* haplotype TC were the two most common in the case and control groups (TT frequencies of 0.633 and 0.657, respectively, and TC frequencies of 0.619 and 0.643, respectively). The*CASP7* haplotype GC was significantly different in patients with PsV than in controls (47.2% versus 54.4%,*p* = 0.0149). We did not identify the other haplotypes to be significantly associated with PsV (*P* \> 0.05).

We also used Haploview to calculate the haplotypes of individual genes on the same chromosome, estimated the haplotype frequencies, and compared the haplotype distribution between the patients and control groups. We found that the haplotype frequency of*CASP3* (rs2705897) on chromosome 4,*CASP7*(rs17090911) on chromosome 10, CASP10 (rs12613347) on chromosome 2, and*CASP12*(rs506601) on chromosome 11 was significantly different between the patients group and the control group. The results are shown in [Table 7](#tab7){ref-type="table"}. We performed the same analysis for the age group under 40 years old and found that the haplotype frequency of*CASP7* (rs17090911) on chromosome 10,*CASP9*(rs4233532) on chromosome 1,*CASP10* (rs12613347) on chromosome 2, and*CASP12*(rs506601) on chromosome 11 was significantly different between the patients group and the control group. The results are shown in [Table 8](#tab8){ref-type="table"}.

4. Discussion {#sec4}
=============

Genome-wide association studies (GWASs) have identified numerous single nucleotide polymorphisms (SNPs) associated with psoriasis risk \[[@B28], [@B29]\]; however, our study was the first to evaluate the association of*CASP* family genes SNPs with risk of PsV in Han population in northeast China. We found that*CASP8* rs6704688 and the*CASP7*haplotype GC were significantly different between cases and controls. These findings suggested that polymorphisms in*CASP7*and*CASP8* were associated with PsV risk in Han population of northeastern China and provide new insights into the importance of*CASP7* and*CASP8* in psoriasis susceptibility.

The apoptotic pathways of keratinocytes mainly include two mechanisms, and the process is regulated by a variety of proteins, genes, and internal and external stimuli. The "extrinsic\" pathway is triggered by the binding of Fas ligand (FasL) or tumor necrosis factor (TNF) to membrane death receptors and these membrane death receptors recruit adapter molecules resulting in the activation of CASP8 \[[@B10]\]. The activated CASP8 then initiates a downstream apoptotic cascade by cleaving CASP3 and/or CASP7 leading to apoptosis. The "intrinsic" pathway includes mitochondrial release of cytochrome c and, along with the cofactor Apaf-1, the formation of an activated CASP9 apoptosome \[[@B10]\]. CASP3 and/or CASP7 are then activated, ultimately leading to apoptosis. Finally, both pathways end with DNA cleavage, which then forms apoptotic bodies and is phagocytosed by neighboring cells.

Human*CASP7*is located on chromosome 10q25.3 and contains 13 exons, and human*CASP8* is located on chromosome 2q33.1 and contains 14 exons. GWAS study suggests that there are significant correlations between SNPs in the vicinity of*CASP7* and*CASP8* and psoriasis (the details are shown in Supplementary Tables [S5](#supplementary-material-1){ref-type="supplementary-material"} and [S6](#supplementary-material-1){ref-type="supplementary-material"}.)*CASP7* and*CASP8*encode CASP7 and CASP8 proteins, respectively. SNPs can strongly influence plasma levels and the biological activities of their corresponding proteins \[[@B30]\]. A six-nucleotide insertion/deletion variant rs3834129, which is located in the*CASP8* promoter region, is associated with decreased risk of various cancers including cutaneous melanoma \[[@B31]--[@B33]\]. rs6704688 is located in the intron region of*CASP8*. While the function of rs6704688 is not yet known, we know that it is located near rs3834129 and is in high LD with rs3834129. Therefore, we inferred that rs6704688 may not be a true causal variant and that the relationship between rs6704688 and PsV could be attributed to the presence of rs3834129 in the population. Computational molecular and biochemical analyses have confirmed that the rs3834129 DEL allele disrupts the binding site of the transcriptional activator Sp1, thereby reducing the transcription and expression of*CASP8* \[[@B32]\]. Low CASP8 expression or functional aberrations may suppress T-lymphocyte apoptosis \[[@B32]\]. T cells and their cytokines play a central role in the pathogenesis of psoriasis \[[@B34]\]. The pathogenic T cells enter the skin, become activated, and release chemokines and cytokines to attract other immune cells to mediate keratinocyte hyperproliferation and maintain the inflammatory process of psoriasis \[[@B34]\]. Studies have shown the DEL allele and DEL carrier of rs3834129 had negative associations with cancer susceptibility in Asian populations and rs6704688 is associated with reduced cancer risk \[[@B13]\]. Combined with our study, we predicted that the T allele and T-carriers of rs6704688 were negatively correlated with the susceptibility to PsV from the additive model, whereas the heterozygous TC genotype had a protective effect from the heterozygous model. In the follow-up, we will conduct a detailed study of rs3834129.

Given the role of CASP7 in apoptosis and inflammation, the associations among CASP7 and autoimmune diseases and cancer susceptibility are important. Their relevance has been reported in insulin-dependent diabetes mellitus, rheumatoid arthritis, childhood leukemia, and different types of human cancers \[[@B18], [@B21]\]. Soung et al. found that a*CASP7* gene inactivating mutation (70 Cys to Tyr mutant) could lead to loss of apoptotic function \[[@B18]\]. Thus, we hypothesized that genetic variations in*CASP7* may act as strong apoptosis signals to block or delay the apoptosis of keratinocyte cells in PsV. The frequency of the haplotype GC in cases was lower than controls, which implied a protective role with regard to cases versus controls.

This study had some limitations. First, it is a hospital-based case-control study and the sample size was relatively small, which may limit the statistical power to explore the real association. In the future, we need to further study the larger sample size and ethnicity to validate our results. Next, we tested limited polymorphisms that were representative in*CASP*genes; these polymorphisms may not be the critical loci for psoriasis but may instead be nearby in LD with a causative locus. Studies on the correlations of more gene loci are needed. Additionally, more comprehensive studies, such as additional clinical studies and functional analyses, are needed to explain and supplement our findings. Despite these limitations, our study demonstrated the association between*CASP7* and*CASP8* polymorphisms and the PsV risk.

5. Conclusions {#sec5}
==============

In conclusion, our findings demonstrated that*CASP7* and*CASP8* gene polymorphisms were associated with PsV risk in Han population of northeastern China. This is the first study describing the relationships between genetic polymorphisms in*CASP* family genes and PsV susceptibility in Han population in northeast China.*CASP7* and*CASP8* gene polymorphisms may be involved in the etiopathogenesis of PsV, and analysis of these polymorphisms could provide new insights into the diagnosis and treatment of PsV.
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###### 

The supplementary materials contain several experimental data and experimental results that are closely related to the content of the manuscript. They are relatively unimportant or large or negative results, but they are still very meaningful for manuscripts.

###### 

Click here for additional data file.

###### 

Characteristics of the study participants.

  Characteristic         cases         controls      P value
  ---------------------- ------------- ------------- ---------
  Total Number           540           612            
  Gender, n (%)                                      0.062
   Male                  332 (0.615)   342 (0.559)    
   Female                208 (0.385)   270 (0.441)    
  Age at onset, n (%)                                 
   ≤40 years             439 (0.813)                  
   \>40 years            101 (0.187)                  
  Mean age ± SD, years   44.23±12.44   45.47±12.73   0.238
  PASI, n (%)                                         
   ≤10                   446 (0.826)                  
   \>10                  94 (0.174)                   
  Familial cases (N)     203 (0.376)                  
  Sporadic cases(N)      337 (0.624)                  

N: number; PASI: psoriasis area and severity index.

###### 

Candidate SNPs analysis.

  ---------------------------------------------------------------------------------------------
  Gene       SNP          Chromosome position   Major/minor\   Risk\    Risk allele frequency
                                                allele         allele   
  ---------- ------------ --------------------- -------------- -------- -----------------------
  *CASP1*    rs2282659    11:105026710          A/G            A        0.804, 0.791

  *CASP3*    rs2705897    4:184631944           T/G            G        0.193, 0.163

             rs4647610    4:184646777           T/C            C        0.359, 0.328

  *CASP4*    rs547584     11:104943160          T/C            C        0.178, 0.157

             rs672016     11:104961127          C/G            G        0.228, 0.222

  *CASP5*    rs507879     11:105007200          T/C            T        0.822, 0.804

  *CASP6*    rs5030545    4:109699714           C/T            C        0.917, 0.913

  *CASP7*    rs17090911   10:113719221          G/A            A        0.094, 0.072

             rs2227310    10:113729393          C/G            G        0.433, 0.384

  *CASP8*    rs6704688    2:201241309           C/T            C        0.769, 0.753

             rs2293554    2:201266864           T/G            T        0.780, 0.758

  *CASP9*    rs4233532    1:15495090            T/C            C        0.416, 0.413

             rs1052576    1:15506048            C/T            T        0.369, 0.368

  *CASP10*   rs12613347   2:201190589           C/T            T        0.357, 0.351

             rs13006529   2:201217736           T/A            T        0.785, 0.783

  *CASP12*   rs506601     11:104899754          A/T            A        0.698, 0.685

  *CASP14*   rs3181304    19:15050098           A/G            G        0.435, 0.413
  ---------------------------------------------------------------------------------------------

SNP: single nucleotide polymorphism.

###### 

The single SNP association studies result of CASPs in cases and controls.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene Symbol   Genotype     Cases\        Controls\     H-W P Value   P Value   Adjusted P Value   Statistical Model   P           P\'         OR\
                             (n=540)       (n= 612)                                                                                             (95%CI)
  ------------- ------------ ------------- ------------- ------------- --------- ------------------ ------------------- ----------- ----------- ---------------
  *CASP1*       rs2282659                                                                                                                        

                GG           24(0.044)     30(0.049)                                                Additive            0.8650      0.8813       

                GA           164(0.304)    196(0.320)    0.7871        0.5945    0.6279             Dominant            0.7952      0.8528      1.083

                AA           352(0.652)    386(0.630)                                               Recessive           0.5977      0.6057      (0.812,1.444)

                G/A          212/868       256/968                                                  heterozygous        0.6687      0.7222       

                             0.196/0.804   0.209/0.791                                                                                           

  *CASP3*       rs2705897                                                                                                                        

                TT           350(0.648)    430(0.703)                                               Additive            0.3765      0.3845       

                TG           172(0.319)    164(0.268)    0.8629        0.1953    0.2205             Dominant            0.1632      0.1833      1.221

                GG           18(0.033)     18(0.029)                                                Recessive           0.7874      0.8057      (0.902,1.653)

                T/G          872/208       1024/200                                                 heterozygous        0.1832      0.2056       

                             0.807/0.193   0.837/0.163                                                                                           

                rs4647610                                                                                                                        

                TT           222(0.411)    274(0.448)                                               Additive            0.5322      0.5412       

                TC           248(0.459)    274(0.448)    0.1773        0.2700    0.2857             Dominant            0.3758      0.4025      1.147

                CC           70(0.130)     64(0.105)                                                Recessive           0.3498      0.3586      (0.899,1.463)

                T/C          692/388       822/402                                                  heterozygous        0.7812      0.7998       

                             0.641/0.359   0.672/0.328                                                                                           

  *CASP4*       rs547584                                                                                                                         

                TT           368(0.681)    434(0.709)                                               Additive            0.5413      0.5451       

                TC           152(0.282)    164(0.268)    0.886         0.3451    0.3884             Dominant            0.4714      0.5293      1.162

                CC           20(0.037)     14(0.023)                                                Recessive           0.3164      0.3403      (0.852,1.585)

                T/C          888/192       1032/192                                                 heterozygous        0.7170      0.7835       

                             0.822/0.178   0.843/0.157                                                                                           

                rs672016                                                                                                                         

                GG           20(0.037)     30(0.049)                                                Additive            0.5789      0.5968       

                GC           206(0.382)    212(0.346)    1             0.8180    0.8317             Dominant            0.4794      0.5470      0.969

                CC           314(0.581)    370(0.605)                                               Recessive           0.5734      0.6178      (0.734,1.278)

                G/C          246/834       272/952                                                  heterozygous        0.3824      0.3873       

                             0.228/0.772   0.222/0.778                                                                                           

  *CASP5*       rs507879                                                                                                                         

                TT           366(0.678)    402(0.657)                                               Additive            0.6168      0.6265       

                TC           156(0.289)    180(0.294)    1             0.4362    0.4632             Dominant            0.5950      0.5992      0.886

                CC           18(0.033)     30(0.049)                                                Recessive           0.3439      0.4141      (0.658,1.194)

                T/C          888/192       984/240                                                  heterozygous        0.8904      0.9258       

                             0.822/0.178   0.804/0.196                                                                                           

  *CASP6*       rs5030545                                                                                                                        

                TT           2(0.004)      0(0)                                                     Additive            0.4295      0.6065       

                TC           86(0.159)     106(0.173)    0.886         0.8369    0.9111             Dominant            \-          0.9998      1.043

                CC           452(0.837)    506(0.827)                                               Recessive           0.7430      0.8257      (0.688,1.580)

                T/C          90/990        106/1118                                                 heterozygous        0.6538      0.6495       

                             0.083/0.917   0.087/0.913                                                                                           

  *CASP7*       rs17090911                                                                                                                       

                GG           442(0.819)    526(0.860)                                               Additive            0.36448     0.4247       

                GA           94(0.174)     84(0.137)     0.8727        0.1609    0.1908             Dominant            0.1810      0.2086      1.346

                AA           4(0.007)      2(0.003)                                                 Recessive           0.4888      0.6035      (0.884,2.051)

                G/A          978/102       1136/88                                                  heterozygous        0.2229      0.2461       

                             0.06/0.094    0.928/0.072                                                                                          

                rs2227310                                                                                                                        

                GG           104(0.193)    88(0.144)                                                Additive            0.2164      0.2147       

                GC           260(0.481)    294(0.480)    0.5244        0.0894    0.0919             Dominant            0.1172      0.1432      0.815

                CC           176(0.326)    230(0.376)                                               Recessive           0.2106      0.2184      (0.644,1.032)

                G/C          468/612       470/754                                                  heterozygous        0.9792      0.9998       

                             0.433/0.567   0.384/0.616                                                                                           

  *CASP8*       rs6704688                                                                                                                        

                TT           40(0.074)     24(0.039)                                                Additive            0.0169*∗*   0.0179*∗*    

                TC           170(0.315)    254(0.415)    0.8725        0.5429    0.5777             Dominant            0.0679      0.0974      1.088

                CC           330(0.611)    334(0.546)                                               Recessive           0.1129      0.1258      (0.829,1.427)

                T/C          250/830       302/922                                                  heterozygous        0.0126*∗*   0.0149*∗*    

                             0.231/0.769   0.247/0.753                                                                                           

                rs2293554                                                                                                                        

                TT           332(0.615)    358(0.585)                                               Additive            0.6952      0.6784       

                TG           178(0.329)    212(0.346)    0.546         0.3999    0.4151             Dominant            0.4656      0.4911      0.886

                GG           30(0.056)     42(0.069)                                                Recessive           0.5166      0.6077      (0.673,1.167)

                T/G          842/238       928/296                                                  heterozygous        0.6711      0.7163       

                             0.780/0.220   0.758/0.242                                                                                           

  *CASP9*       rs4233532                                                                                                                        

                TT           176(0.326)    224(0.366)                                               Additive            0.2005      0.2144       

                TC           278(0.515)    270(0.441)    0.0447        0.9114    0.9544             Dominant            0.3129      0.3380      1.013

                CC           86(0.159)     118(0.193)                                               Recessive           0.2915      0.3272      (0.801,1.281)

                T/C          630/450       718/506                                                  heterozygous        0.0773      0.0821       

                             0.584/0.416   0.587/0.413                                                                                           

                rs1052576                                                                                                                        

                TT           70(0.130)     98(0.160)                                                Additive            0.2790      0.2851       

                TC           258(0.478)    254(0.415)    1             0.9761    0.9999             Dominant            0.2994      0.3467      0.996

                CC           212(0.392)    260(0.425)                                               Recessive           0.4321      0.4519      (0.784,1.266)

                T/C          398/682       450/774                                                  heterozygous        0.1304      0.1623       

                             0.369/0.631   0.368/0.632                                                                                           

  *CASP10*      rs12613347                                                                                                                       

                TT           74(0.137)     82(0.134)                                                Additive            0.9752      0.9714       

                TC           238(0.441)    266(0.435)    0.6406        0.8325    0.8550             Dominant            0.9150      0.9998      0.974

                CC           228(0.422)    264(0.431)                                               Recessive           0.8247      0.8681      (0.764,1.240)

                T/C          386/694       430/794                                                  heterozygous        0.8829      0.9316       

                             0.357/0.643   0.351/0.649                                                                                           

                rs13006529                                                                                                                       

                TT           342(0.633)    366(0.598)                                               Additive            0.0846      0.0806       

                TA           164(0.304)    226(0.369)    0.4431        0.9179    0.9452             Dominant            0.3849      0.3863      0.985

                AA           34(0.063)     20(0.033)                                                Recessive           0.0856      0.1072      (0.744,1.305)

                T/A          848/232       958/266                                                  heterozygous        0.0965      0.1112       

                             0.785/0.215   0.783/0.217                                                                                           

  *CASP12*      rs506601                                                                                                                         

                TT           48(0.089)     48(0.078)                                                Additive            0.5086      0.5049       

                TA           230(0.426)    290(0.484)    0.6716        0.6101    0.6427             Dominant            0.6507      0.7603      1.065

                AA           262(0.485)    274(0.448)                                               Recessive           0.3682      0.4018      (0.829,1.369)

                T/A          326/754       386/838                                                  heterozygous        0.2485      0.2688       

                             0.302/0.698   0.315/0.685                                                                                          

  *CASP14*      rs3181304                                                                                                                        

                GG           120(0.222)    104(0.170)                                               Additive            0.2007      0.2129       

                GA           230(0.426)    298(0.487)    1             0.4686    0.4826             Dominant            0.1139      0.1425      0.915

                AA           190(0.352)    210(0.343)                                               Recessive           0.8265      0.8582      (0.724,1.156)

                G/A          470/610       506/718                                                  heterozygous        0.1424      0.1547       

                             0.435/0.565   0.413/0.587                                                                                           
  -------------------------------------------------------------------------------------------------------------------------------------------------------------

*∗*: Significant, compared by paired t test; H-W: Hardy--Weinberg equilibrium test; P: model-based statistical p value; P\': p value adjusted by permutation; OR: odds ratio; and 95%CI: 95% confidence interval.

###### 

Significant results of intergenic interaction analysis of all samples.

  SNP (Chr.)      SNP (Chr.)      OR_INT   Chi-square   P
  --------------- --------------- -------- ------------ --------
  rs12613347(2)   rs672016(11)    1.87     6.8995       0.0086
  rs13006529(2)   rs506601(11)    0.384    6.6773       0.0098
  rs13006529(2)   rs4647610(4)    3.039    6.0643       0.0138
  rs4233532(1)    rs13006529(2)   0.430    4.9705       0.0258
  rs6704688(2)    rs4647610(4)    0.54     4.6476       0.0311
  rs12613347(2)   rs2282659(11)   0.41     4.6218       0.0316
  rs506601(11)    rs2282659(11)   0.43     4.5832       0.0323
  rs6704688(2)    rs672016(11)    0.58     4.5381       0.0332

SNP: single nucleotide polymorphism; Chr.: chromosome of single nucleotide polymorphism; OR_INT: odds ratio for interaction; P: p-value.

###### 

Significant results of intergene interaction analysis of samples less than 40 years old.

  SNP (Chr.)      SNP (Chr.)       OR_INT   Chi-square   P
  --------------- ---------------- -------- ------------ --------
  rs13006529(2)   rs6704688(2)     4.85     8.9000       0.0029
  rs5030545(4)    rs2705897(4)     0.12     6.1767       0.0129
  rs4647610(4)    rs547584(11)     2.90     5.9144       0.0150
  rs2293554(2)    rs4647610(4)     2.45     5.2208       0.0223
  rs4233532(1)    rs1052576(1)     0.50     4.9522       0.0261
  rs5030545(4)    rs4647610(4)     0.24     4.6047       0.0319
  rs6704688(2)    rs2282659(11)    0.34     4.2747       0.0387
  rs5030545(4)    rs17090911(10)   0.08     4.0495       0.0442
  rs4233532(1)    rs2227310(10)    1.82     3.9662       0.0464
  rs13006529(2)   rs2282659(11)    0.34     3.9280       0.0475

SNP: single nucleotide polymorphism; Chr.: chromosome of single nucleotide polymorphism; OR_INT: odds ratio for interaction; P: p-value.

###### 

The haplotype analyses result of CASPs in cases and controls.

  Gene     Haplotype   Freq.   Case, Control Ratio Counts       Case, Control Frequencies   Chi Square   P Value
  -------- ----------- ------- -------------------------------- --------------------------- ------------ -------------
  CASP3    TT          0.646   341.8  : 198.2, 401.9  : 210.1   0.633, 0.657                0.712        0.3989
           TC          0.177   94.2  : 445.8, 110.1  : 501.9    0.174, 0.180                0.057        0.8118
           GC          0.166   99.8  : 440.2, 90.9  : 521.1     0.185, 0.149                2.721        0.099
           GT          0.012   4.2  : 535.8, 9.1  : 602.9       0.008, 0.015                1.234        0.2666
  CASP4    TC          0.632   334.5  : 205.5, 393.5  : 218.5   0.619, 0.643                0.685        0.408
           TG          0.201   109.5  : 430.5, 122.5  : 489.5   0.203, 0.200                0.013        0.911
           CC          0.143   82.5  : 457.5, 82.5  : 529.5     0.153, 0.135                0.758        0.384
           CG          0.023   13.5  : 526.5, 13.5  : 598.5     0.025, 0.022                0.106        0.7446
  CASP7    GC          0.51    255.0  : 285.0, 333.0  : 279.0   0.472, 0.544                5.934        0.0149^*∗*^
           GG          0.407   234.0  : 306.0, 235.0  : 377.0   0.433, 0.384                2.894        0.0889
           AC          0.082   51.0  : 489.0, 44.0  : 568.0     0.094, 0.072                1.928        0.165
  CASP8    CT          0.546   304.0  : 236.0, 325.2  : 286.8   0.563, 0.531                1.157        0.282
           TT          0.222   117.0  : 423.0, 138.8  : 473.2   0.217, 0.227                0.172        0.6787
           CG          0.214   111.0  : 429.0, 135.8  : 476.2   0.205, 0.222                0.457        0.4991
           TG          0.018   8.0  : 532.0, 12.2  : 599.8      0.015, 0.020                0.43         0.5121
  CASP9    TC          0.582   314.9  : 225.1, 355.9  : 256.1   0.583, 0.582                0.003        0.9559
           CT          0.365   198.9  : 341.1, 221.9  : 390.1   0.368, 0.363                0.041        0.8397
           CC          0.05    26.1  : 513.9, 31.1  : 580.9     0.048, 0.051                0.037        0.8465
  CASP10   CT          0.431   232.3  : 307.7, 264.4  : 347.6   0.430, 0.432                0.004        0.9506
           TT          0.353   191.7  : 348.3, 214.6  : 397.4   0.355, 0.351                0.023        0.8783
           CA          0.215   114.7  : 425.3, 132.6  : 479.4   0.212, 0.217                0.031        0.8596

*∗*: significant; Freq.: frequencies.

###### 

Haplotype analysis of SNPs on the same chromosome for all samples.

  Chr.   SNP          Haplotype   Ca-freq.   N-Ca (540)   Co-freq.   N-Co ( 612)   P
  ------ ------------ ----------- ---------- ------------ ---------- ------------- ---------
  1      rs4233532    CC          0.048      25.92        0.053      32.436        0.9226
         rs1052576    CT          0.369      199.26       0.364      222.768        
                      TC          0.583      314.82       0.583      356.796        
  11     rs506601     ACCCG       0.034      18.36        0.027      16.524        0.0093
         rs547584     ACCTA       0.116      62.64        0.102      62.424         
         rs672016     ACGTA       0.028      15.12        0.023      14.076         
         rs507879     ATCCG       0.057      30.78        0.067      41.004         
         rs2282659    ATCTA       0.265      143.1        0.277      169.524        
                      ATCTG       0.014      7.56         0.022      13.464         
                      ATGCG       0.049      26.46        0.041      25.092         
                      ATGTA       0.141      76.14        0.139      85.068         
                      TTCCG       0.033      17.82        0.047      28.764         
                      TTCTA       0.245      132.3        0.238      145.656        
                      TTCTG       0.018      9.72         0          0              
                      TTGTA       0          0            0.017      10.404         
  10     rs17090911   AC          0.094      50.76        0.072      44.064        0.0448
         rs2227310    GC          0.473      255.42       0.544      332.928        
                      GG          0.433      233.82       0.384      235.008        
  2      rs12613347   CACT        0          0            0.012      7.344         0.0038
         rs13006529   CATG        0          0            0.01       6.12           
         rs6704688    CATT        0.2        108          0.196      119.952        
         rs2293554    CTCG        0.159      85.86        0.164      100.368        
                      CTCT        0.263      142.02       0.248      151.776        
                      CTTT        0.023      12.42        0.023      14.076         
                      TTCG        0.05       27           0.064      39.168         
                      TTCT        0.305      164.7        0.268      164.016        
                      TTTT        0          0            0.015      9.18           
  4      rs2705897    CGC         0.179      96.66        0.124      75.888        0.00004
         rs4647610    CGT         0          0            0.016      9.792          
         rs5030545    CTC         0.164      88.56        0.161      98.532         
                      CTT         0.576      311.04       0.613      375.156        
                      TGC         0          0            0.023      14.076         
                      TTC         0.017      9.18         0.02       12.24          
                      TTT         0.064      34.56        0.043      26.316         

Chr.: chromosome; SNP: single nucleotide polymorphism; N-Ca: number of case group; Ca-freq.: case group frequencies; N-Co: number of control group; Co-freq.: control group frequencies; P: p value.

###### 

Haplotype analysis of SNPs on the same chromosome for samples under 40 years old.

  chr   SNP          Haplotype   Ca-freq   N-Ca ( 439)   Co-freq   N-Co (216)   P
  ----- ------------ ----------- --------- ------------- --------- ------------ ---------
  1     rs4233532    CC          0.545     239.255       0.051     11.016       0.00000
        rs1052576    CT          0.401     176.039       0.338     73.008        
                     TC          0.054     23.706        0.611     131.976       
  11    rs506601     ACCCG       0.042     18.438        0.019     4.104        0.00098
        rs547584     ACCTA       0.119     52.241        0.105     22.68         
        rs672016     ACGTA       0.035     15.365        0.024     5.184         
                     ATCCA       0         0             0.019     4.104         
        rs507879     ATCCG       0.027     11.853        0.058     12.528        
        rs2282659    ATCTA       0.309     135.651       0.224     48.384        
                     ATCTG       0.015     6.585         0.038     8.208         
                     ATGCG       0.053     23.267        0.043     9.288         
                     ATGTA       0.117     51.363        0.172     37.152        
                     TTCCG       0.026     11.414        0.054     11.664        
                     TTCTA       0.227     99.653        0.229     49.464        
                     TTCTG       0.018     7.902         0         0             
                     TTGTA       0.012     5.268         0.015     3.24          
  10    rs17090911   AC          0.094     41.266        0.102     22.032       0.08798
        rs2227310    GC          0.436     191.404       0.518     111.888       
                     GG          0.47      206.33        0.38      82.08         
  2     rs12613347   CACT        0         0             0.015     3.24         0.00000
        rs13006529   CATT        0.176     77.264        0.187     40.392        
        rs6704688    CTCC        0         0             0.161     34.776        
        rs2293554    CTCG        0.198     86.922        0         0             
                     CTCT        0.289     126.871       0.294     63.504        
                     CTTT        0         0             0.028     6.048         
                     TTCC        0         0             0.073     15.768        
                     TTCG        0.075     32.925        0         0             
                     TTCT        0.262     115.018       0.226     48.816        
                     TTTT        0         0             0.016     3.456         
  4     rs2705897    CGC         0.176     77.264        0.107     23.112       0.00001
        rs4647610    CGT         0         0             0.011     2.376         
        rs5030545    CTC         0.183     80.337        0.182     39.312        
                     CTT         0.533     233.987       0.644     139.104       
                     TGC         0         0             0.02      4.32          
                     TTC         0.014     6.146         0.016     3.456         
                     TTT         0.094     41.266        0.02      4.32          

Chr, Chromosome; SNP, single nucleotide polymorphism; N-Ca, number of case group; Ca-freq, case group frequencies; N-Co, Number of control group; Co-freq, control group frequencies; P, p value.
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